Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says

Candel Therapeutics (NASDAQ:CADL) had its target price lifted by stock analysts at Bank of America from $9.00 to $12.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s target price would indicate a potential upside of 2.04% from the company’s previous close.

A number of other analysts have also recently weighed in on CADL. Stifel Nicolaus initiated coverage on shares of Candel Therapeutics in a research note on Monday, July 13th. They issued a “buy” rating and a $22.00 price objective for the company. Wall Street Zen upgraded shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Cantor Fitzgerald began coverage on shares of Candel Therapeutics in a research report on Monday, April 20th. They set an “overweight” rating for the company. HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Candel Therapeutics in a report on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Friday, July 17th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.29.

Candel Therapeutics Stock Down 0.3%

Shares of CADL traded down $0.04 during trading hours on Friday, hitting $11.76. 1,358,791 shares of the company were exchanged, compared to its average volume of 1,527,929. The company has a debt-to-equity ratio of 0.34, a quick ratio of 28.05 and a current ratio of 28.05. The company has a market cap of $861.66 million, a PE ratio of -11.98 and a beta of -0.51. The firm’s 50 day moving average is $9.62 and its 200-day moving average is $7.37. Candel Therapeutics has a 52 week low of $4.35 and a 52 week high of $11.93.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.25). On average, equities research analysts forecast that Candel Therapeutics will post -0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Francesca Barone sold 23,447 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the transaction, the insider directly owned 77,362 shares in the company, valued at $778,261.72. This represents a 23.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.02, for a total transaction of $70,140.00. Following the completion of the sale, the chief technology officer directly owned 83,865 shares of the company’s stock, valued at approximately $840,327.30. This trade represents a 7.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 14.30% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CADL. BNP Paribas Financial Markets raised its holdings in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after acquiring an additional 4,439 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Candel Therapeutics by 361.7% during the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after purchasing an additional 7,527 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Candel Therapeutics during the fourth quarter valued at approximately $51,000. ProShare Advisors LLC acquired a new position in shares of Candel Therapeutics in the fourth quarter valued at $59,000. Finally, Invesco Ltd. acquired a new position in shares of Candel Therapeutics in the first quarter valued at $59,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics News Roundup

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $23 price target, implying substantial upside from the stock’s recent level near $11.63. The firm expects Candel to become profitable in future years, forecasting EPS of $0.69 in fiscal 2028 and $1.41 in fiscal 2029. Benzinga analyst rating article
• Positive Sentiment: Candel continues to target a biologics license application submission in the fourth quarter for its prostate cancer candidate, with management highlighting meaningful execution toward the filing. The company is also aiming for its first commercial product in 2027, providing a potential catalyst if regulatory milestones remain on schedule. CADL commercial product and BLA article
• Neutral Sentiment: The company provided second-quarter 2026 financial results and a corporate update as investors assess its development timeline, financing needs, and progress toward commercialization. Candel Therapeutics second-quarter results
• Negative Sentiment: Candel reported a quarterly loss of $0.52 per share, substantially worse than the consensus loss estimate of $0.27. The company remains unprofitable, with analysts expecting a full-year loss of $0.91 per share. Candel earnings press release
• Negative Sentiment: HC Wainwright modestly reduced its long-term EPS forecasts, cutting fiscal 2028 expectations from $0.71 to $0.69 and fiscal 2029 expectations from $1.45 to $1.41. Although the firm remains bullish, the revisions signal slightly lower anticipated profitability.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.